Oxford, UK – 13 March 2023: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Company”), a leading gene and cell therapy group, notes the statement by the US Treasury, Federal Reserve, and FDIC on 12 March 2023 announcing measures to protect all depositors of Silicon Valley Bank ("SVB") in the United States.
Oxford Biomedica Solutions LLC, the Company’s U.S. based subsidiary, maintains both a checking and deposit account with SVB. The Company has no accounts with SVB in the UK. Oxford Biomedica confirms it has no balance sheet risk exposure to the SVB receivership issue.
Oxford Biomedica plc:
Stuart Paynter, Chief Financial Officer – T: +44 (0)1865 783 000
Taylor Boyd, VP, Head of IR – T: +1 (984) 268 8488 / E: firstname.lastname@example.org
Sophia Bolhassan, VP, Corporate Affairs and IR – T: +44 (0) 7394 562 425 / E: email@example.com
Consilium Strategic Communications:
T: +44 (0)20 3709 5700 / E: firstname.lastname@example.org
Mary-Jane Elliott / Matthew Cole / Matthew Neal
About Oxford Biomedica
Oxford Biomedica (LSE:OXB) is an innovative leading viral vector specialist focused on delivering life changing therapies to patients.
Oxford Biomedica plc and its subsidiaries (the Group) work across key viral vector delivery systems including those based on lentivirus, adeno-associated virus (AAV) and adenovirus, providing innovative solutions to cell and gene therapy biotechnology and biopharma companies for their process development, analytical development and manufacturing needs. Oxford Biomedica has built a sector leading lentiviral vector delivery system, LentiVector® platform, and is working on programmes from pre-clinical to commercial stage across a range of therapeutic areas with global partners.
Oxford Biomedica is based across several locations and headquartered in Oxfordshire, UK. In 2022, the Group established Oxford Biomedica Solutions, a US based subsidiary AAV manufacturing and innovation business, based near Boston, US.
Further information is available at www.oxb.com.